ABSTRACT

In spondyloarthropathic patients, inflammatory back and hip pain may interfere with the pain caused by infection or malignancy. Newly developed inflammatory pain, especially in patients under anti-TNF therapy, is important because of the risk of infection and controversial malignancy of these agents. Therefore, a careful differential diagnosis must be performed before the newly developed pain that can be attributed to disease activation. In this spondyloarthropathic case under adalimumab treatment lymphoma was diagnosed and discussed as a result of differential diagnosis of inflammatory back and hip pain.